- Home
- BEAM vs SYNA Comparison
BEAM vs SYNA Comparison
Compare BEAM & SYNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- SYNA
- Stock Information
- Founded
- BEAM 2017
- SYNA 1986
- Country
- BEAM United States
- SYNA United States
- Employees
- BEAM N/A
- SYNA N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- SYNA Computer peripheral equipment
- Sector
- BEAM Health Care
- SYNA Technology
- Exchange
- BEAM Nasdaq
- SYNA Nasdaq
- Market Cap
- BEAM 1.8B
- SYNA 2.0B
- IPO Year
- BEAM 2020
- SYNA 2002
- Fundamental
- Price
- BEAM $17.00
- SYNA $49.07
- Analyst Decision
- BEAM Strong Buy
- SYNA Buy
- Analyst Count
- BEAM 11
- SYNA 10
- Target Price
- BEAM $50.50
- SYNA $96.67
- AVG Volume (30 Days)
- BEAM 3.0M
- SYNA 687.7K
- Earning Date
- BEAM 05-06-2025
- SYNA 05-08-2025
- Dividend Yield
- BEAM N/A
- SYNA N/A
- EPS Growth
- BEAM N/A
- SYNA N/A
- EPS
- BEAM N/A
- SYNA 4.20
- Revenue
- BEAM $63,518,000.00
- SYNA $1,009,600,000.00
- Revenue This Year
- BEAM N/A
- SYNA $13.20
- Revenue Next Year
- BEAM $6.32
- SYNA $10.04
- P/E Ratio
- BEAM N/A
- SYNA $11.67
- Revenue Growth
- BEAM N/A
- SYNA N/A
- 52 Week Low
- BEAM $13.53
- SYNA $41.80
- 52 Week High
- BEAM $35.25
- SYNA $98.00
- Technical
- Relative Strength Index (RSI)
- BEAM 40.71
- SYNA 37.81
- Support Level
- BEAM $16.04
- SYNA $46.37
- Resistance Level
- BEAM $17.94
- SYNA $50.88
- Average True Range (ATR)
- BEAM 1.84
- SYNA 4.23
- MACD
- BEAM 0.26
- SYNA -0.17
- Stochastic Oscillator
- BEAM 44.24
- SYNA 31.89
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About SYNA Synaptics Incorporated $0.001 Par Value
Synaptics Inc is a producer of semiconductor solutions for the mobile, PC, and Internet of Things markets. The company develops human interface solutions that enable touch, display, fingerprint, video, audio, voice, AI, and connectivity functions for smartphones, PCs, Internet of Things products, and other electronic devices. Geographically, it derives a majority of revenue from China. The company operates in one segment: the development, marketing, and sale of semiconductor products used in electronic devices and products.